Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Апрель 29, 2024
Abstract
Fixed
dose
combinations
(FDCs)
incorporating
two
or
three
medicines
in
a
single
inhaler
have
been
created
to
enhance
patient
compliance
and
hence
clinical
outcomes.
However,
the
development
of
dry
powder
inhalers
(DPIs),
particularly
for
FDCs,
faces
challenges
pertinent
formulation
uniformity
reproducibility.
Therefore,
this
project
aimed
employ
nanotechnology
develop
FDC
DPIs
market-leading
medicines—fluticasone
propionate
(FP)
salmeterol
xinafoate
(SAL)—for
asthma
management.
Nanoaggregates
were
prepared
using
novel
biocompatible
biodegradable
poly(ester
amide)
based
on
amino
acid
tyrosine,
utilising
one-step
interfacial
polymerisation
process.
The
produced
tyrosine
poly
(ester
drug-loaded
nanoparticles
evaluated
content
uniformity,
PSA,
FTIR,
TEM,
DSC,
XRD
aerodynamic
performance
(in
vitro
vivo).
optimised
demonstrated
high
entrapment
efficiency–
>
90%.
terms
emitted
dose,
fine
particle
fraction
respirable
was
superior
carrier-based
marketed
product.
In-vivo
studies
showed
that
FP
(above
formulation)
SAL
reached
lungs
mice
reproducible
manner.
These
results
highlight
superiority
FP/SAL
via
process,
which
can
be
used
as
cost-effective
efficient
method
alleviate
burden
asthma.
Pharmaceutics,
Год журнала:
2023,
Номер
15(8), С. 2151 - 2151
Опубликована: Авг. 17, 2023
Chronic
inflammatory
respiratory
diseases,
such
as
asthma,
chronic
obstructive
pulmonary
disease
(COPD),
and
cystic
fibrosis,
present
ongoing
challenges
in
terms
of
effective
treatment
management.
These
diseases
are
characterized
by
persistent
inflammation
the
airways,
leading
to
structural
changes
compromised
lung
function.
There
several
treatments
available
for
them,
bronchodilators,
immunomodulators,
oxygen
therapy.
However,
there
still
some
shortcomings
effectiveness
side
effects
drugs.
To
achieve
optimal
therapeutic
outcomes
while
minimizing
systemic
effects,
targeted
therapies
precise
drug
delivery
systems
crucial
management
these
diseases.
This
comprehensive
review
focuses
on
role
particularly
nanoparticle-based
systems,
inhaled
corticosteroids
(ICSs),
novel
biologicals,
gene
therapy,
personalized
medicine.
By
examining
latest
advancements
strategies
areas,
we
aim
provide
a
thorough
understanding
current
landscape
future
prospects
improving
challenging
conditions.
Journal of Controlled Release,
Год журнала:
2024,
Номер
370, С. 195 - 209
Опубликована: Апрель 25, 2024
The
bioaerogel
microparticles
have
been
recently
developed
for
respiratory
drug
delivery
and
attract
fast
increasing
interests.
These
highly
porous
ultralow
density
hence
possess
much
reduced
aerodynamic
diameter,
which
favour
them
with
greatly
enhanced
dispersibility
improved
aerosolisation
behaviour.
adjustable
particle
geometric
dimensions
by
varying
preparation
methods
controlling
operation
parameters
make
it
possible
to
fabricate
accurate
sizes
efficient
the
targeted
regions
of
tract
(i.e.
intranasal
pulmonary).
Additionally,
technical
process
can
provide
opportunities
accommodating
polar,
weak
polar
non-polar
drugs
at
sufficient
amount
satisfy
clinical
needs,
adsorbed
are
primarily
in
amorphous
form
that
potentially
facilitate
dissolution
improve
bioavailability.
Finally,
nature
biopolymers
further
offer
additional
advantageous
characteristics
mucoadhesion,
sustained
release
subsequently
elongated
time
continuous
treatment
on-site.
fascinating
features
strongly
support
become
a
novel
platform
effective
wide
range
regions,
increased
residence
on-site,
release,
constant
local
systemic
diseases
anticipated
better-quality
therapeutic
effects.
Journal of Controlled Release,
Год журнала:
2024,
Номер
373, С. 410 - 425
Опубликована: Июль 24, 2024
Dry
powder
inhalers
(DPIs)
are
widely
employed
to
treat
respiratory
diseases,
offering
numerous
advantages
such
as
high
dose
capacity
and
stable
formulations.
However,
they
usually
face
challenges
in
achieving
sufficient
pulmonary
drug
delivery
minimizing
excessive
oropharyngeal
deposition.
This
review
provides
a
new
viewpoint
address
these
by
focusing
on
the
role
of
swirling
flow,
crucial
yet
under-researched
aspect
that
induces
strong
turbulence.
In
review,
we
comprehensively
discuss
both
key
classic
designs
(tangential
inlet,
chamber,
grid
mesh,
mouthpiece)
innovative
inhalers,
exploring
how
induced
flow
initiates
dispersion
promotes
efficiency.
Valuable
design
considerations
effectively
coordinate
with
formulations
patients
also
provided.
It
is
highlighted
delicate
manipulation
essential
maximize
benefits.
By
emphasizing
its
potential
application,
this
offers
promising
insights
for
advancing
DPI
technology
optimizing
therapeutic
outcomes
inhaled
therapy.
Viruses,
Год журнала:
2025,
Номер
17(2), С. 252 - 252
Опубликована: Фев. 12, 2025
Inhaled
dry
powder
formulations
of
antiviral
agents
represent
a
novel
and
potentially
transformative
approach
to
managing
respiratory
viral
infections.
Traditional
therapies
in
the
form
tablets
or
capsules
often
face
limitations
terms
therapeutic
activity,
systemic
side
effects,
delayed
onset
action.
Dry
inhalers
(DPIs)
provide
targeted
delivery
system,
ensuring
direct
administration
antivirals
infection
site,
tract,
which
enhance
efficacy
minimize
exposure.
This
review
explores
current
state
inhaled
agents,
their
advantages
over
traditional
routes,
specific
under
development.
We
discuss
benefits
delivery,
such
as
improved
drug
deposition
lungs
reduced
alongside
considerations
related
formulation
preparation.
In
addition,
we
summarize
developed
(published
marketed)
powders
agents.
Research Journal of Pharmacy and Technology,
Год журнала:
2025,
Номер
unknown, С. 436 - 444
Опубликована: Янв. 27, 2025
Respiratory
infections
pose
a
significant
global
threat
to
public
health,
contributing
substantially
morbidity
and
mortality.
This
review
explores
the
evolution
of
inhalation
therapy,
focusing
on
transition
from
traditional
Metered
Dose
Inhalers
(MDIs)
contemporary
Dry
Powder
(DPIs),
which
have
become
pivotal
in
drug
delivery
lungs.
The
narrative
begins
with
early
nebulizers
atomizers,
progressing
through
challenges
developments
MDIs,
ultimately
leading
emergence
DPIs.
meticulously
examines
advantages
DPIs
over
encompassing
technological
innovations,
enhanced
patient
experiences,
clinical
efficiency
across
various
respiratory
conditions.
Regulatory
milestones
market
dynamics
are
scrutinized,
highlighting
shifts
preferences
among
healthcare
professionals
patients.
Challenges
encountered
DPI
development
discussed,
offering
insights
into
obstacles
potential
solutions.
article
addresses
future
prospects
exploring
emerging
technologies
ongoing
research.
In
summary,
this
comprehensive
evaluation
underscores
profound
impact
transitioning
delivery,
aiming
be
valuable
resource
for
research,
clinical,
industry
navigating
dynamic
landscape
therapy.
